Disease · MONDO_0002120
neuroendocrine carcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. neuroendocrine carcinoma. Diseases, record MONDO_0002120. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002120
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs89
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LUTETIUM OXODOTREOTIDE LU-177 | CHEMBL4297545 | Protein | Approval | TTD | 4 | 2 | 1 | Drugs and targets |
| IOBENGUANE I 123 | CHEMBL1615777 | Small molecule | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| RETIFANLIMAB | CHEMBL4298037 | Antibody | Approval | TTD | 1 | 0 | 0 | Drugs and targets |
| IRINOTECAN | CHEMBL481 | Small molecule | Phase 3 | ClinicalTrials.gov | 12 | 12 | 10 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 10 | 8 | Drugs and targets |
| SURUFATINIB | CHEMBL4297190 | Small molecule | Phase 3 | ClinicalTrials.gov and TTD | 6 | 5 | 5 | Drugs and targets |
| TORIPALIMAB | CHEMBL4297843 | Antibody | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| TARLATAMAB | CHEMBL5095292 | Antibody | Phase 3 | ClinicalTrials.gov | 4 | 3 | 3 | Drugs and targets |
| LEUCOVORIN CALCIUM | CHEMBL1201138 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| SELINEXOR | CHEMBL3545185 | Small molecule | Phase 3 | TTD | 1 | 0 | 0 | Drugs and targets |
1 to 10 of 89
See all 89 drugsTargets120
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PDCD1 | Programmed cell death protein 1 | 10 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Approval | https://conductscience.org/library/genes/5133 | Drugs and targets |
| CD274 | Programmed cell death 1 ligand 1 | 4 | Programmed cell death 1 ligand 1 inhibitor; Programmed cell death 1 ligand 1 other | Phase 2/3 | https://conductscience.org/library/genes/29126 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 3 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| SSTR1 | Somatostatin receptor | 3 | Somatostatin receptor 1 agonist; Somatostatin receptor agonist; Somatostatin receptor binding agent | Approval | https://conductscience.org/library/genes/6751 | Drugs and targets |
| SSTR2 | Somatostatin receptor | 3 | Somatostatin receptor 2 agonist; Somatostatin receptor agonist; Somatostatin receptor binding agent | Approval | https://conductscience.org/library/genes/6752 | Drugs and targets |
| SSTR3 | Somatostatin receptor | 3 | Somatostatin receptor 3 agonist; Somatostatin receptor agonist; Somatostatin receptor binding agent | Approval | https://conductscience.org/library/genes/6753 | Drugs and targets |
| SSTR5 | Somatostatin receptor | 3 | Somatostatin receptor 5 agonist; Somatostatin receptor agonist; Somatostatin receptor binding agent | Approval | https://conductscience.org/library/genes/6755 | Drugs and targets |
| DLL3 | Delta-like protein 3 | 2 | Delta-like protein 3 binding agent | Phase 3 | https://conductscience.org/library/genes/10683 | Drugs and targets |
| HTR1B | 5-hydroxytryptamine receptor 1B | 2 | Serotonin 1b (5-HT1b) receptor agonist | Phase 1 | https://conductscience.org/library/genes/3351 | Drugs and targets |
| HTR1D | 5-hydroxytryptamine receptor 1D | 2 | Serotonin 1d (5-HT1d) receptor agonist | Phase 1 | https://conductscience.org/library/genes/3352 | Drugs and targets |
1 to 10 of 120
See all 120 targetsTrials78
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02709889 | Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors | Phase 1/2 | 200 | 2020-10-19 | Malignant Melanoma, Medullary Thyroid Cancer, Glioblastoma, Large-Cell Neuroendocrine Carcinoma, Neuroendocrine Prostate Cancer, High Grade Gastroenteropancreatic Neuroendocrine Carcinoma, Other Neuroendocrine Carcinoma, Other Solid Tumors | ROVALPITUZUMAB TESIRINE | Its record names the disease | ClinicalTrials.gov |
| NCT00113360 | RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma | Phase 2 | 67 | 2010-12-07 | Neuroendocrine Carcinoma, Islet Cell Carcinoma | EVEROLIMUS, OCTREOTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01218555 | Study of Everolimus (RAD001) in Combination With Lenalidomide | Phase 1 | 44 | 2022-01-27 | Solid Organ Malignancies, Adenoidcystic Carcinoma, Neuroendocrine Tumors | EVEROLIMUS, LENALIDOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01121939 | Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers | Phase 2 | 43 | 2015-09-23 | Neuroendocrine Carcinoma | BEVACIZUMAB, OCTREOTIDE, PERTUZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00607113 | Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma | Phase 2 | 41 | 2013-05-08 | Neuroendocrine Carcinoma | BEVACIZUMAB, EVEROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT03136055 | Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas | Phase 2 | 36 | 2022-12-27 | High Grade Malignant Neuroendocrine Carcinoma (Diagnosis) | PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01253161 | Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs) | Phase 2 | 29 | 2022-01-18 | Neuroendocrine Tumors, Carcinoid Tumors | PASIREOTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT04079712 | Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors | Phase 2 | 17 | 2025-12-12 | Metastatic Large Cell Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma, Metastatic Neuroendocrine Neoplasm, Metastatic Small Cell Neuroendocrine Carcinoma | CABOZANTINIB, IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03736720 | Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin | Phase 2 | 11 | 2023-12-19 | Locally Advanced Digestive System Neuroendocrine Carcinoma, Locally Advanced Pancreatic Neuroendocrine Carcinoma, Metastatic Digestive System Neuroendocrine Carcinoma, Metastatic Pancreatic Neuroendocrine Carcinoma, Refractory Digestive System Neuroendocrine Carcinoma, Refractory Pancreatic Neuroendocrine Carcinoma, Unresectable Digestive System Neuroendocrine Carcinoma, Unresectable Pancreatic Neuroendocrine Carcinoma | FLUOROURACIL, IRINOTECAN, LEUCOVORIN CALCIUM | Its record names the disease | ClinicalTrials.gov |
| NCT03190213 | Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine Carcinoma | Phase 2 | 6 | 2020-01-27 | Neuroendocrine Tumors | PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 78
See all 78 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Part A: Pembrolizumab Only vs Part B: Pembrolizumab + Chemotherapy: deaths from any cause | 11 of 14 | 21 of 22 | 36 | NCT03136055 | Trial comparisons |
| Part A: Pembrolizumab Only vs Part B: Pembrolizumab + Chemotherapy: serious adverse events | 1 of 14 | 6 of 22 | 36 | NCT03136055 | Trial comparisons |
Papers from its trials34
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 36739879 | RESULT | 1 | PubMed |
| 42949119 | DERIVED | 1 | PubMed |
| 42129445 | DERIVED | 1 | PubMed |
| 42081171 | DERIVED | 1 | PubMed |
| 41968073 | DERIVED | 1 | PubMed |
| 41791703 | DERIVED | 1 | PubMed |
| 41572426 | DERIVED | 1 | PubMed |
| 41231502 | DERIVED | 1 | PubMed |
| 40963055 | DERIVED | 1 | PubMed |
| 40608313 | DERIVED | 1 | PubMed |
1 to 10 of 34
See all 34 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002120
GET https://conductscience.org/api/diseases/v1/MONDO_0002120/drugs?page=2